IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

23 Apr 2025 10:04:00 By Nasdaq GlobeNewswire

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

10 Feb 2025 09:35:00 By Nasdaq GlobeNewswire

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

07 Jan 2025 09:34:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

19 Dec 2024 09:35:00 By Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

16 Dec 2024 09:48:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

10 Dec 2024 09:39:00 By Nasdaq GlobeNewswire

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

09 Dec 2024 09:33:00 By Nasdaq GlobeNewswire

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

25 Nov 2024 09:32:00 By Nasdaq GlobeNewswire

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

02 Oct 2024 09:32:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

19 Sep 2024 09:31:00 By Nasdaq GlobeNewswire

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

28 Aug 2024 09:32:00 By Nasdaq GlobeNewswire

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

25 Jul 2024 21:31:00 By Nasdaq GlobeNewswire

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

08 Jul 2024 09:31:00 By Nasdaq GlobeNewswire

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

17 Jun 2024 09:35:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

10 May 2024 09:35:00 By Nasdaq GlobeNewswire

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

29 Apr 2024 09:39:00 By Nasdaq GlobeNewswire

Immix Biopharma on Track to Dose NXC-201 Patients in United States

18 Apr 2024 09:32:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 Apr 2024 09:36:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

20 Mar 2024 09:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

05 Mar 2024 09:35:00 By Nasdaq GlobeNewswire